Baxter International Stock Forecast for 2023 - 2025 - 2030
Updated on 02/04/2023
Baxter International Stock Forecast and Price Target
Baxter International's most recent price target of $58.00 for 2023 was provided by six renowned analysts over the past few months, with an average prediction of $58.00. If this prediction is correct, Baxter International's stock could rise by 24.25 percent from its current trading price. The potential increase for the stock is $58.00 per share, with a possible range of $51.00 to $85.00. If you're thinking of investing in BAX stock, it might be good to look at its rivals too.
24.25% Upside
Baxter International Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Baxter International's Price has grown from $77.92 to $84.98 – a 9.06% increase. Next year, analysts are expecting Fair Value to reach $114.64 – an increase of 34.90%. Over the next eight years, the forecast is for Fair Value to grow by 69.86%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
11
|
$164.61 | $181.05 | 9.65% |
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$339.08 | $333.19 | 17.97% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$44.06 | $53.97 | 19.50% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
8
|
£10.58k | £153.20 | -98.53% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF85.77 | CHF103.75 | 9.89% |
Baxter International Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Baxter International's Revenue has grown from $11.36B to $12.78B – a 12.52% increase. Next year, analysts are expecting Revenue to reach $16.65B – an increase of 30.23%. Over the next eight years, the forecast is for Revenue to grow by 45.11%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ABT Stock Forecast | Abbott Laboratories | Outperform |
10
|
$111.79 | $120.97 | 11.82% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$74.45 | $80.99 | 11.48% |
| CSL Stock Forecast | CSL | Outperform |
8
|
$313.81 | $218.60 | -27.96% |
Baxter International Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, Baxter International's Dividend per Share has grown by 28.24%, rising from $0.85 to $1.09. For next year, analysts predict Dividend per Share of $1.31, which would mean an increase of 20.18%. Over the next eight years, experts predict that Baxter International's Dividend per Share will grow at a rate of 59.42%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ISRG Stock Forecast | Intuitive Surgical Inc | Outperform |
15
|
$254.68 | $273.80 | 10.73% |
| GE Stock Forecast | General Electric | Outperform |
9
|
$81.96 | $86.47 | 6.15% |
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$245.84 | $268.00 | 11.86% |
Baxter International Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Baxter International's Free Cash Flow has grown, rising from $1.41B to $1.48B – a growth of 5.04%. In the next year, analysts believe that Free Cash Flow will reach $2.10B – an increase of 41.92%. For the next eight years, the forecast is for Free Cash Flow to grow by 108.43%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| MMM Stock Forecast | 3M | Hold |
16
|
$117.49 | $147.79 | 1.71% |
| BSX Stock Forecast | Boston Scientific | Outperform |
15
|
$48.50 | $50.77 | 3.09% |
| EW Stock Forecast | Edwards Lifesciences | Outperform |
15
|
$82.12 | $92.45 | 13.25% |
Baxter International Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Baxter International's Net Income has grown by 28.27%, rising from $1.00B to $1.28B. For next year, analysts predict Net Income of $2.47B, which would mean an increase of 92.46%. Over the next eight years, experts predict that Baxter International's Net Income will grow at a rate of 143.03%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| AME Stock Forecast | AMETEK Inc | Outperform |
17
|
$146.38 | $153.41 | 4.52% |
| RMD Stock Forecast | ResMed | Outperform |
17
|
$224.60 | $251.67 | 12.42% |
| HOLX Stock Forecast | Hologic Inc | Outperform |
8
|
$84.68 | $79.86 | -2.57% |
Baxter International EBITDA Forecast for 2023 - 2025 - 2030
Baxter International's EBITDA has grown In the last two years, rising from $2.61B to $2.98B – a growth of 14.39%. In the next year, analysts believe that EBITDA will reach $4.16B – an increase of 39.69%. For the next eight years, experts predict that Baxter International's EBITDA will grow at a rate of 60.47%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| FRE Stock Forecast | Fresenius SE & Co. KGaA | Outperform |
18
|
27.11€ | 35.72€ | 19.88% |
| PKI Stock Forecast | PerkinElmer | Outperform |
16
|
$138.56 | $159.83 | 17.28% |
| PHIA Stock Forecast | Koninklijke Philips N.V. | Outperform |
18
|
15.33€ | 50.07€ | 98.96% |
Baxter International EBIT Forecast for 2023 - 2025 - 2030
Baxter International's EBIT has seen impressive growth In the last two years, rising from $1.82B to $2.09B – a growth of 14.76%. In the next year, analysts believe that EBIT will reach $3.37B – an increase of 61.10%. For the next eight years, the forecast is for EBIT to grow by 94.95%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| FME Stock Forecast | Fresenius Medical Care AG & Co... | Hold |
18
|
35.61€ | 42.10€ | -10.14% |
| PEN Stock Forecast | Penumbra | Buy |
9
|
$261.02 | $0.00 | 11.10% |
| GRF Stock Forecast | Grifols | Outperform |
18
|
13.65€ | 27.25€ | 55.31% |
Baxter International EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Baxter International's EPS has grown from $3.31 to $3.61 – a 9.06% increase. Next year, analysts are expecting EPS to reach $4.87 – an increase of 34.90%. Over the next eight years, the forecast is for EPS to grow by 69.86%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| DVA Stock Forecast | DaVita Inc | Hold |
16
|
$85.48 | $81.79 | -8.17% |
| GMED Stock Forecast | Globus Medical | Outperform |
16
|
$79.63 | $73.08 | -3.93% |
| 002007 Stock Forecast | Hualan Biological Engineering | Outperform |
18
|
¥23.20 | ¥42.59 | 12.07% |